AG
ARRY

Artal Group’s Array Biopharma Inc ARRY Stock Holding History

Artal Group’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,000,000
Closed -$48.8M – 127
2019
Q1 		$48.8M Sell
2,000,000
-500,000
-20% -$10.4M 1.99% 12
2018
Q4 		$35.6M Buy
2,500,000
+600,000
+32% +$9.1M 1.32% 17
2018
Q3 		$28.9M Sell
1,900,000
-100,000
-5% -$1.53M 0.75% 22
2018
Q2 		$33.6M Hold
2,000,000
– – 0.71% 20
2018
Q1 		$32.6M Buy
2,000,000
+500,000
+33% +$8.01M 0.41% 25
2017
Q4 		$19.2M Hold
1,500,000
– – 0.29% 29
2017
Q3 		$18.4M Buy
1,500,000
+550,000
+58% +$5.11M 0.32% 26
2017
Q2 		$7.95M Buy
950,000
+200,000
+27% +$1.64M 0.14% 40
2017
Q1 		$6.71M Sell
750,000
-500,000
-40% -$5.32M 0.15% 51
2016
Q4 		$11M Sell
1,250,000
-2,250,000
-64% -$16.6M 0.24% 35
2016
Q3 		$23.6M Sell
3,500,000
-370,000
-10% -$1.43M 0.47% 23
2016
Q2 		$13.8M Buy
3,870,000
+160,000
+4% +$521K 0.28% 28
2016
Q1 		$10.9M Hold
3,710,000
– – 0.21% 30
2015
Q4 		$15.7M Hold
3,710,000
– – 0.29% 37
2015
Q3 		$16.9M Hold
3,710,000
– – 0.38% 37
2015
Q2 		$26.7M Hold
3,710,000
– – 1.15% 27
2015
Q1 		$27.3M Buy
3,710,000
+710,000
+24% +$5.05M 1.26% 21
2014
Q4 		$14.2M Hold
3,000,000
– – 0.5% 36
2014
Q3 		$10.7M Hold
3,000,000
– – 0.39% 43
2014
Q2 		$13.7M Hold
3,000,000
– – 0.55% 39
2014
Q1 		$14.1M Hold
3,000,000
– – 0.51% 42
2013
Q4 		$15M Hold
3,000,000
– – 0.54% 37
2013
Q3 		$18.7M Hold
3,000,000
– – 0.61% 24
2013
Q2 		$13.6M Buy
+3,000,000
New +$16.1M 0.43% 33

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group's ARRY Position: Q2 2019 in Review

Artal Group sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 2,000,000 shares — an estimated $48.8M sold.

Artal Group first reported a position in ARRY in Q2 2013 and held it in 24 quarters. The position peaked at $48.8M in Q1 2019. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Artal Group reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Artal Group sold 2,000,000 Array Biopharma Inc shares in Q2 2019, an estimated $48.8M.
  • Artal Group first reported a position in Array Biopharma Inc in Q2 2013 and held it in 24 quarters.
  • Artal Group's Array Biopharma Inc position peaked at $48.8M in Q1 2019.
  • 319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.